Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

Innovent · Phase 2 · Active, not recruiting · Enrollment 141

NCT06862908

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
IBI362 4.0mgn/rn/rn/rn/r
placebon/rn/rn/rn/r
IBI362 6.0mgn/rn/rn/rn/r

Not shown

  • IBI362 4.0mg: endpoint not reported
  • placebo: endpoint not reported
  • IBI362 6.0mg: endpoint not reported